Parsortix Launch at Circulate Conference in Berlin

For immediate release

18 February 2014

 

ANGLE plc

 

PARSORTIX LAUNCH AT CIRCULATE CONFERENCE IN BERLIN

 

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that it is launching its Parsortix non-invasive cancer diagnostics system at the 4^th Annual Circulate conference in Berlin on 19 and 20 February 2014.

 

Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of circulating tumour cells (CTCs) and circulating cancer biomarkers.

 

At the conference, Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey, will present initial data from a study entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies'.  Mr Nageswaran used ANGLE's Parsortix system to carry out the study.

 

ANGLE's Parsortix system enables the capture of CTCs from cancer patient blood for mutational analysis. The Parsortix system uses a simple blood test to capture the cancer cells for analysis in contrast to the established solid tumour biopsy process where cells are surgically removed from the primary tumour.  The Company's liquid biopsy has key medical advantages in that (i) being a simple blood test, it is non-invasive (ii) it can be used for inaccessible tumours where a solid biopsy is not possible or is very difficult and (iii) it can be repeated as often as required during the patient's treatment, which is important as the patient's cancer mutates over time.

 

Following ANGLE's successful deployment of the Parsortix system with key opinion leaders, and the Company's success in securing a CE Mark for the product, ANGLE is now making the Parsortix system available for sale to the European clinical market.

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We believe that the ability of our patented Parsortix system to capture CTCs from patient blood opens a wide range of potential applications in treating cancer patients and we look forward to attending the Circulate conference and discussing that capability with key industry, medical and research players involved in personalised cancer care. We also look forward to Mr Nageswaran's presentation and his insight into the medical significance of the Parsortix system."

 

 

For further information:

 

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles	020 7466 5000